Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04761406 · ClinicalTrials.gov registry record · NA
Microalgae Extract Phaeosol Combined to Exercise in Healthy Overweight Women : Efficacy on Body Weight Management
A NA study of Overweight and Obesity and Exercise, sponsored by Microphyt.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT04761406: Completed NA study of Overweight and Obesity and Exercise, sponsored by Microphyt.
NCT04761406 is a NA study of Overweight and Obesity and Exercise that has completed, run by Microphyt. The registered enrollment target is 60 participants, below the 228-participant average among 115 other Overweight and Obesity trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04761406, a NA study of Overweight and Obesity and Exercise, has completed, sponsored by Microphyt.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
PhaoeSOL (Microphyt, Baillargues, France) is a microalgae-based nutritional ingredient developed with a patented production process that has New Dietary Ingredient (NDI) status from the FDA (#1120). It is an extract of the microalgae Phaeodactylum tricornutum standardized to 2.0% Fucoxanthin (FX) content by adding a food grade medium-chain triglyceride (MCT)-oil and a tocopherol-rich (Vitamin E) extract (0.5 % w:w). PhaeoSOL is intended for use as a source of the naturally occurring carotenoid, fucoxanthin, in food supplement products for the general population at levels not to exceed 437 mg/person/day for a maximal duration of 30 days of PhaeoSOL (equivalent to 10 mg fucoxanthin/person/day). Prior studies suggest that marine algae and Fucoxanthinol may have anti-obesity, lipid lowering, and glucose management enhancing properties. The purpose of this proof of concept pilot study is to examine whether dietary supplementation of PhaoeSOL enhances the benefits of women participating in an exercise and weight management program.
Primary Outcome
Difference in body fat mass (kg) evaluated by DEXA between weeks 6 and 12 compared to baseline.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Phaeosol group
- DIETARY_SUPPLEMENT Placebo group
Study Locations (1)
Texas
- Exercise & Sport Nutrition Lab - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-04-26 |
| Est. Completion | 2023-11-01 |
| Phase | NA |
What the finished NCT04761406 record still lists
NCT04761406 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 228-participant average among 115 other Overweight and Obesity trials with a reported enrollment target (74% lower).
The record links to 5 conditions, with Overweight and Obesity appearing as the primary indexed condition, and to 2 interventions - of which Phaeosol group is the first listed.
NCT04761406 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04761406 about?
NCT04761406 is a clinical study titled "Microalgae Extract Phaeosol Combined to Exercise in Healthy Overweight Women : Efficacy on Body Weight Management". PhaoeSOL (Microphyt, Baillargues, France) is a microalgae-based nutritional ingredient developed with a patented production process that has New Dietary Ingredient (NDI) status from the FDA (#1120). It is an extract of the microalgae Phaeodactylum tricornutum standardized to 2.0% Fucoxanthin (FX) co...
What is the current status of trial NCT04761406?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2021-04-26. Estimated completion is 2023-11-01.
What conditions does trial NCT04761406 study?
This clinical trial studies the following conditions: Overweight and Obesity, Exercise, Healthy Lifestyle, Body Weight Changes, Dietary Supplement.
What interventions are being tested in trial NCT04761406?
The interventions under investigation include: Phaeosol group (DIETARY_SUPPLEMENT), Placebo group (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04761406?
This trial is sponsored by Microphyt, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04761406 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overweight and Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04761406's enrollment target sits among peer trials
60 79th of 115 higher than 34 of 115 other Overweight and Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overweight and Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
A Pilot Factorial Trial of an Integrated Lifestyle Intervention
RECRUITING · NA
-
Cottonseed Oil Dose Response
RECRUITING · NA
-
Cooking Skills to Improve Long-Term Weight Loss in Young Adults With Intellectual Disabilities
RECRUITING · NA
-
Testing the Adipose Expandability Hypothesis in Vivo During Overfeeding
RECRUITING · NA
-
Cottonseed Oil Versus Matched PUFA Effects
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI